INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
WEIGHT-LOSS DRUG TRACKER

Semaglutide

Semaglutide is a GLP-1 receptor agonist used in distinct products. A molecule name does not establish that every brand, formulation, or proposed use has the same approval.

A single official Wegovy 1.5 mg oral semaglutide carton in an outside-US presentation.
Official Wegovy oral-tablet carton in the outside-US presentation supplied by Novo Nordisk. Packaging varies by market; this image is not dosing advice. Image: Novo Nordisk. Official Wegovy media kit: https://www.novonordisk.com/news-and-media/wegovy-media-kit.html

Semaglutide is a GLP-1 receptor agonist used in distinct products. A molecule name does not establish that every brand, formulation, or proposed use has the same approval.

Wegovy is a weight-management product; Ozempic’s cited EU record concerns type 2 diabetes. Brand names listed here are examples, not a complete global product inventory. Use the current information for the exact product and country.

STEP 1 evaluated injected semaglutide in adults without diabetes over 68 weeks. SELECT separately evaluated cardiovascular outcomes in adults with established cardiovascular disease and overweight or obesity without diabetes. The populations and outcomes should not be combined into a guaranteed personal result.

The US label includes contraindications and important warnings. This record neither reproduces every restriction nor provides dose conversions between formulations. A clinician and pharmacist should interpret the applicable product information.

Regulatory status checked on 3 October 2026

United States: Wegovy formulations are FDA-approved for specified uses. Higher-dose Wegovy HD was approved on 19 March 2026. Approval is formulation- and indication-specific; this record does not extend every use to all semaglutide brands.

European Union: EMA Wegovy record documents EU authorisation for weight management, with injection/tablet and age-specific restrictions. Ozempic has a separate diabetes product record.

Official records and primary evidence

Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.

Official references

  1. US Wegovy prescribing information ↗
  2. FDA Wegovy supplemental approval letter ↗
  3. EU Wegovy product record ↗
  4. EU Ozempic product record ↗
  5. STEP 1 original trial abstract ↗
  6. SELECT cardiovascular outcomes trial ↗

Clinical trial evidence

Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.

STEP 1

NCT03548935 · Semaglutide profile

Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed
Registry enrollment
1961 (actual)
Published analysis population
1961
Analysis time point
68 weeks
Population
Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
Registry checked
2026-10-03

Registry actual enrollment and published enrolled population both equal 1961.

Published mean body-weight change at 68 weeks · treatment-policy: regardless of discontinuation or rescue intervention
Historical trial armMean change from baseline
semaglutide 2.4 mg trial arm-14.9%
placebo-2.4%

Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.

Original study abstract · Full registry record

The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.

Evidence, explainers and reporting

The medicine profile is a reference point. These articles address narrower questions and developments.

← Back to the drug tracker
Cookie policy